Video: Oral Upadacitinib Proves Effective for Adults, Adolescents with Atopic Dermatitis
Upadacitinib, a novel JAK inhibitor, induced clear or almost clear skin among many adults and adolescents with atopic dermatitis.
Emma Guttman-Yassky, MD, PhD, chair of the department of dermatology at the Icahn School of Medicine at Mount Sinai, spoke with MD/ alert about the research and the significant impact this drug could have on patients if approved.
Press Release
New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results
Dec 09, 2022 View All Press Releases